Remote prescribing for elective non-surgical cosmetic procedures is prohibited in the UK. The NMC, GMC, and JCCP all require that any prescription-only medicine used in an aesthetic treatment is prescribed following an in-person clinical assessment of the patient. Telephone consultations, video calls, and online requests do not satisfy this requirement.
What Is the Remote Prescribing Ban in Aesthetics?
Botulinum toxin is a prescription-only medicine (POM) in the UK under the Human Medicines Regulations 2012. A valid prescription from a legally authorised prescriber is required before it can be administered. That has been the legal position for some time.
What shifted in 2025 was the explicit, coordinated ban on prescribing via remote methods for non-surgical cosmetic use. The NMC confirmed from 1 June 2025 that independent nurse and midwife prescribers must conduct a face-to-face consultation and document a clinical assessment before prescribing any product used in an elective non-surgical cosmetic procedure. The NMC's position is explicit: prescribing by telephone, email, online platform, video, or communication via a third party is "not appropriate" for these medicines.
The GMC's prescribing standards reach the same conclusion through a different route. Doctors must not prescribe cosmetic prescription medicines without a physical examination. A remote consultation does not allow the level of clinical assessment needed to prescribe safely in this context.
Which Regulators Prohibit Remote Prescribing for Cosmetic Procedures?
The ban is not a position held by one regulator. It is a point of alignment across every professional body with authority over aesthetics prescribing in the UK.
NMC (Nursing and Midwifery Council): From 1 June 2025, independent nurse and midwife prescribers are required to see each patient face-to-face before prescribing any cosmetic POM. This applies to initial consultations and to follow-up treatments.
GMC (General Medical Council): GMC prescribing standards require doctors to carry out a physical examination where clinically appropriate. For elective cosmetic procedures involving POMs, examination is clinically necessary. Prescribing at the request of a third party for a patient not personally assessed does not meet the standard.
JCCP (Joint Council for Cosmetic Practitioners): The JCCP's published position is unequivocal. Remote prescribing for injectable, topical, or oral prescription medication used in non-surgical cosmetic treatments is "not acceptable in any circumstances." The CPSA (Cosmetic Practice Standards Authority) is a co-signatory to the same position. The ban covers botulinum toxin, hyaluronidase, cosmetic POMs classified as dermal filler products, local anaesthetics, lipolysis agents, and tissue stimulants.
Where one regulator's position might be characterised as cautious, three major bodies taking the same position in formal published statements represents a settled professional standard.
What "Face-to-Face" Means in This Context
The NMC and GMC are consistent: a video consultation, however thorough, does not meet the face-to-face requirement. The patient must be physically present with the prescriber for the consultation to satisfy the standard.
That in-person assessment must precede the prescription. The prescriber must:
- Assess the patient in person before any prescription is issued
- Document the clinical assessment contemporaneously in the patient record
- Form an independent clinical judgment about whether treatment is appropriate
- Not issue a prescription based solely on information supplied by the practitioner who will administer the treatment
The third-party referral model, where a non-prescribing practitioner consults the patient and then requests a prescription from a prescriber who has not seen the patient, is specifically prohibited. The prescriber who issues a prescription without personally assessing the patient is acting outside the standards set by the NMC and GMC.
For practices relying on remote prescribers, including services offering online or phone consultation prescribing to independent aesthetic nurses, this is a material change to how the practice can lawfully operate.
Who Does the Ban Apply To?
The ban applies to every category of prescriber working in aesthetics in the UK:
- Independent nurse prescribers under the NMC's position from June 2025
- Medical doctors under GMC prescribing standards
- Dentist prescribers under comparable GDC standards
- Pharmacist prescribers under GPhC prescribing requirements, which demand adequate clinical assessment before prescribing
Non-prescribers, meaning the majority of aesthetic practitioners who administer botulinum toxin but do not personally hold prescribing rights, are indirectly affected. Any non-prescribing practitioner who administers a cosmetic POM must be working under a prescription issued by a prescriber who has assessed the patient face-to-face. If the prescription was obtained remotely, the entire chain of supply is outside regulatory standards.
Practitioners with a standing arrangement with a remote prescribing service need to review that arrangement. If the prescriber is not seeing each patient in person, the prescription does not meet the regulatory standard.
Remote Prescribing and the UK Aesthetics Licensing Scheme
England's aesthetics licensing scheme, introduced under the Health and Care Act 2022 and being staged across local authorities, sits alongside the prescribing standards rather than replacing them. A licensed practice is still subject to the NMC, GMC, and JCCP prescribing requirements. A local authority licence does not authorise a different standard of clinical governance.
The aesthetic regulation framework is designed to layer these requirements. Holding a licence while relying on a remote prescribing arrangement would create a compliance gap at the governance level, not only at the professional standards level. Local authorities assessing licence applications review clinical governance arrangements, including prescribing models. An arrangement prohibited by the NMC and GMC is unlikely to satisfy a licensing authority's clinical governance requirements.
The JCCP's standards make active compliance with all applicable professional standards a condition of listing on its register. Reliance on remote prescribing would be a breach of JCCP registration conditions alongside the relevant statutory regulator's standards.
What Practitioners Need to Do
For practitioners who hold an independent prescribing qualification and prescribe for their own patients, the implication is clear: see every patient in person before issuing any prescription for cosmetic use. This applies at each treatment episode, not only the initial consultation.
For non-prescribing practitioners relying on a prescriber, the question is whether that prescriber is seeing each patient personally before issuing a prescription. If not, the practice is operating outside regulatory standards. Practical steps:
- Get written confirmation. Ask the prescribing party to confirm in writing that they conduct a face-to-face clinical assessment of each patient before issuing any cosmetic prescription.
- Review indemnity coverage. Non-compliant prescribing is a material deviation from clinical standards. Inform your insurer if there is any doubt about the compliance of the prescribing arrangement.
- Contact your regulator directly. Nurses should approach the NMC. Doctors should contact the GMC. Neither regulator has published an exception to the requirement; direct confirmation from the regulator is the appropriate step if any ambiguity remains.
- Document the transition. If moving from a remote to an in-person prescribing model, record the change with a date and a description of the new arrangements.
From Regulation to Reputation™ is £200 off until 20 July, £299 instead of £499, with code REG299. Bernadette wrote the book on this subject, Regulation to Reputation: mastering successful aesthetic practice, and the course is the structured programme built on that work. It covers the prescribing framework, clinical governance, and the practical steps that keep a practice compliant as the regulatory landscape develops. See the full course catalogue to see where it sits alongside the other clinical programmes.
FAQ
Is remote prescribing for botulinum toxin illegal in the UK?
Botulinum toxin is a prescription-only medicine under UK law, and prescribing it remotely for cosmetic use places the prescriber outside the professional standards set by the NMC, GMC, and JCCP. Whether it constitutes a criminal offence depends on the specific circumstances, but it is a clear breach of professional regulatory requirements and grounds for fitness-to-practise proceedings.
Does the remote prescribing ban apply to follow-up treatments?
Yes. The NMC's position applies to initial consultations and to follow-up treatments. Each course of treatment requires an in-person assessment before the prescription is issued, not only at the first appointment.
Can a video consultation satisfy the face-to-face requirement?
No. The NMC, GMC, and JCCP all specify that telephone, video, online, and email consultations do not meet the requirement. The patient must be physically present with the prescriber.
What is a "third-party prescribing" arrangement and why is it prohibited?
A third-party arrangement is one where a practitioner who will administer a cosmetic POM requests a prescription from a prescriber who has not personally assessed the patient. This model allowed some independent practices to separate the prescribing and administration roles using a remote prescriber. It is not permitted under the current regulatory standards. The prescriber must see the patient before prescribing.
Does the ban affect all cosmetic injectables or only botulinum toxin?
The JCCP's position extends to all prescription medicines used in non-surgical cosmetic treatments: botulinum toxin, hyaluronidase, local anaesthetics classified as POMs, lipolysis agents, and tissue stimulants. Cosmetic products that are not prescription medicines are not within scope of the prescribing ban, but carry their own classification and governance requirements.
How does this connect to the UK aesthetics licensing scheme?
England's licensing scheme requires practices to demonstrate appropriate clinical governance. A prescribing arrangement that falls outside NMC, GMC, and JCCP standards would not satisfy the governance expectations of a licence holder. Compliance with prescribing standards is a condition of holding a licence, not a separate administrative consideration. See the regulation overview for a fuller picture of how the requirements interact.